Načítá se...
Etiology of Ibrutinib Discontinuation and Outcomes in Chronic Lymphocytic Leukemia Patients
IMPORTANCE: The Bruton’s Tyrosine Kinase inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuation from this drug and outcomes following discontinuation have not been evaluated outside of clinical trials with relatively short follow-up. OBJECTI...
Uloženo v:
| Vydáno v: | JAMA Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4520535/ https://ncbi.nlm.nih.gov/pubmed/26182309 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2014.218 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|